KZIA
KAZIA THERAPEUTICS LTD
$14.28
+13.88%
$163.2M
No data for this timeframe.
Vol
Market Cap$163.2M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (89%)
Inst. Holders9 funds
Inst. Value$3.6M
Inst. Activity2 buys / 0 sells
SEC Reports7
Recent Activity
Jun 2, 2026
SEC
Kazia Therapeutics announced the appointment of James Levine as Chief Financial Officer, effective June 1, 2026. Mr. Lev
6-K — Impact 3/10
May 26, 2026
SEC
Kazia Therapeutics announced expansion of its Phase 1b trial of paxalisib in advanced TNBC from 12 to 36 patients follow
6-K — Impact 5/10
Apr 27, 2026
SEC
Kazia Therapeutics released an investor presentation highlighting positive clinical data for its lead asset paxalisib, i
6-K — Impact 7/10
Inst.
RHUMBLINE ADVISERS — DOUBLED
1,565 shares ($10.8K)
Inst.
MORGAN STANLEY — DOUBLED
1,000 shares ($6.9K)
Apr 23, 2026
short_interest
FTD: KZIA — 388,088 shares ($4.5M) failed to deliver
Settlement: 20260423, Price: $11.53, FTD Value: $4,474,654.64, KAZIA THERAPEUTICS LTD SPONSOR
Price Targets
$26.00
+82.1% upside
Strong Buy
Current $14.28
Low $17.65
Median $27.11
High $32.12
4 analysts
$17.65
$32.12
Analyst Ratings
2Strong Buy
6Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 11, 2026 | Lake Street | INITIATE | Buy |
| Apr 15, 2026 | Laidlaw & Co. | INITIATE | Buy |
| Jan 28, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.00 | $-0.00 — $-0.00 | 1 | |
| Next Q | $-0.00 | $-0.00 — $-0.00 | 1 | |
| Current FY | $-0.02 ▲ +15.0% | $-0.02 — $-0.02 | 100% YoY | 2 |
| Next FY | $-0.02 ▼ -55.0% | $-0.03 — $-0.02 | -29% YoY | 2 |
Latest Reports
NEUTRAL
6-K
3/10
Kazia Therapeutics announced the appointment of James Levine as Chief Financial Officer, effective June 1, 2026. Mr. Lev
Jun 2, 2026
BULLISH
6-K
5/10
Kazia Therapeutics announced expansion of its Phase 1b trial of paxalisib in advanced TNBC from 12 to 36 patients follow
May 26, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| Point72 Asset Management, L.P. | $1.5M | — |
| BALYASNY ASSET MANAGEMENT L.P. | $1.4M | — |
| ROYAL BANK OF CANADA | $255.0K | — |
| BARCLAYS PLC | $178.6K | — |
| RAYMOND JAMES FINANCIAL INC | $117.2K | — |
9 institutional holders with $3.6M total value (482,305 shares) as of 2026-Q1. Top holders: Point72, BALYASNY, ROYAL.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | Point72 Asset Management, L.P. | 200,000 | $1.5M | 41.5% | — |
| 2 | BALYASNY ASSET MANAGEMENT L.P. | 193,114 | $1.4M | 40.0% | — |
| 3 | ROYAL BANK OF CANADA | 34,340 | $255.0K | 7.1% | — |
| 4 | BARCLAYS PLC | 23,999 | $178.6K | 5.0% | — |
| 5 | RAYMOND JAMES FINANCIAL INC | 15,749 | $117.2K | 3.3% | — |
| 6 | Rockefeller Capital Management L.P. | 12,700 | $94.5K | 2.6% | — |
| 7 | RHUMBLINE ADVISERS | 1,402 | $10.4K | 0.3% | DOUBLED +164.8% |
| 8 | MORGAN STANLEY | 1,000 | $7.4K | 0.2% | DOUBLED +400.0% |
| 9 | Allworth Financial LP | 1 | $8.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RHUMBLINE ADVISERS | DOUBLED | 591 | 1,565 | +164.8% | $10.8K | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 200 | 1,000 | +400.0% | $6.9K | 2025-Q4 |
| CITADEL ADVISORS LLC | DOUBLED | 4,566 | 60,476 | +1224.5% | $26.0K | 2024-Q3 |
| RHUMBLINE ADVISERS | ADD | 17,615 | 27,806 | +57.9% | $12.0K | 2024-Q3 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
7 SEC filing reports analyzed. Sentiment: 4 bullish, 0 bearish, 1 mixed, 2 neutral. Avg impact: 5.6/10.
NEUTRAL
6-K
3/10
Kazia Therapeutics announced the appointment of James Levine as Chief Financial Officer, effective J
Jun 2, 2026
BULLISH
6-K
5/10
Kazia Therapeutics announced expansion of its Phase 1b trial of paxalisib in advanced TNBC from 12 t
May 26, 2026
BULLISH
6-K
7/10
Kazia Therapeutics released an investor presentation highlighting positive clinical data for its lea
Apr 27, 2026
BULLISH
6-K
7/10
Kazia Therapeutics appointed Dr. Sudha Rao as Chief Scientific Officer (CSO) effective April 13, 202
Apr 15, 2026
BULLISH
6-K
7/10
Kazia Therapeutics has in-licensed a first-in-class SETDB1-targeted epigenetic drug development plat
Apr 13, 2026
MIXED
6-K
6/10
Kazia Therapeutics reported a half-year loss of $12.55M (up from $10.45M) with strong cash generatio
Mar 30, 2026
NEUTRAL
EFFECT
4/10
Kazia Therapeutics' shelf registration (Form F-3) has become effective, allowing the company to issu
Mar 30, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (89% buy). Based on 9 analysts: 2 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$26.00 mean target
+82.1% upside
Strong Buy (1.50)
$17.65 Low
$32.12 High
| Metric | Value |
|---|---|
| Current Price | $14.28 |
| Target Low | $17.65 |
| Target Mean | $26.00 |
| Target Median | $27.11 |
| Target High | $32.12 |
| # Analysts | 4 |
| Recommendation | Strong Buy (1.50) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-03-31 |
$-0.00 | $-0.00 | $-0.00 | — | — | — | $0.0B | — | 1 |
| Next Q 2026-06-30 |
$-0.00 | $-0.00 | $-0.00 | — | — | — | $0.0B | — | 1 |
| Current FY 2026-06-30 |
$-0.02 | $-0.02 | $-0.02 | 99.9% | +15.0% | 1↑ 0↓ | $0.0B | -81.2% | 2 |
| Next FY 2027-06-30 |
$-0.02 | $-0.03 | $-0.02 | -28.5% | -55.0% | 0↑ 1↓ | $0.0B | -67.2% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.004 | |
| 7d ago | $0.000 | -0.004 |
| 30d ago | $0.000 | -0.004 |
| 60d ago | $0.000 | -0.004 |
| 90d ago | $0.000 | -0.004 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 11, 2026 | Lake Street | INITIATE | — | Buy |
| Apr 15, 2026 | Laidlaw & Co. | INITIATE | — | Buy |
| Jan 28, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| May 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Apr 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Mar 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Jan 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 28, 2026
Clinical Trial
GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases
Phase Phase 2 — TERMINATED
Apr 23, 2026
short_interest
FTD: KZIA — 388,088 shares ($4.5M) failed to deliver
Settlement: 20260423, Price: $11.53, FTD Value: $4,474,654.64, KAZIA THERAPEUTICS LTD SPONSOR
Apr 8, 2026
short_interest
FTD: KZIA — 53,733 shares ($0.5M) failed to deliver
Settlement: 20260408, Price: $9.62, FTD Value: $516,911.46, KAZIA THERAPEUTICS LTD SPONSOR